X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1292) 1292
Publication (116) 116
Book Review (11) 11
Book Chapter (7) 7
Book / eBook (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (884) 884
index medicus (681) 681
animals (520) 520
male (378) 378
serine proteinase inhibitors - therapeutic use (339) 339
female (314) 314
middle aged (204) 204
serine proteinase inhibitors - pharmacology (190) 190
mice (188) 188
serine (173) 173
serine proteinase inhibitors - adverse effects (172) 172
proteases (164) 164
proteins (157) 157
aged (154) 154
treatment outcome (149) 149
adult (148) 148
protease inhibitors (143) 143
analysis (137) 137
biochemistry & molecular biology (136) 136
pharmacology & pharmacy (136) 136
serine proteinase inhibitors - administration & dosage (124) 124
serine proteinase (123) 123
apoptosis (113) 113
health aspects (112) 112
rats (111) 111
cardiac & cardiovascular systems (107) 107
surgery (98) 98
gastroenterology & hepatology (97) 97
thrombin (97) 97
risk factors (95) 95
serine endopeptidases - metabolism (95) 95
cardiopulmonary bypass (92) 92
cell biology (92) 92
enzymes (92) 92
inflammation (92) 92
respiratory system (87) 87
drug therapy, combination (85) 85
research (84) 84
medicine (82) 82
antiviral agents - therapeutic use (81) 81
expression (79) 79
hepatitis c, chronic - drug therapy (79) 79
multidisciplinary sciences (76) 76
aprotinin - therapeutic use (74) 74
care and treatment (74) 74
hepatitis c (74) 74
research article (74) 74
activation (73) 73
protease (73) 73
aprotinin (72) 72
article (72) 72
disease models, animal (72) 72
serine-protease (71) 71
time factors (71) 71
cancer (70) 70
gene expression (69) 69
immunology (69) 69
science (68) 68
inhibition (66) 66
proteinase inhibitors (66) 66
oncology (64) 64
protease inhibitor (63) 63
serine proteases (63) 63
peripheral vascular disease (62) 62
hepacivirus - drug effects (61) 61
dose-response relationship, drug (58) 58
inhibitors (58) 58
hematology (57) 57
therapy (57) 57
aprotinin - adverse effects (56) 56
hepacivirus - genetics (55) 55
hepatitis c virus (55) 55
ribavirin - therapeutic use (55) 55
abridged index medicus (54) 54
apoptosis - drug effects (54) 54
physiological aspects (53) 53
amino acid sequence (52) 52
antiviral agents (52) 52
genetic aspects (52) 52
interferon-alpha - therapeutic use (52) 52
double-blind method (51) 51
in-vitro (50) 50
proteolysis (50) 50
ribavirin (50) 50
signal transduction (49) 49
inhibitor (48) 48
polyethylene glycols - therapeutic use (48) 48
trypsin (48) 48
biochemistry (47) 47
phosphorylation (47) 47
serine proteinase inhibitors - chemistry (47) 47
telaprevir (47) 47
glycine - analogs & derivatives (46) 46
recombinant proteins - therapeutic use (46) 46
cardiopulmonary bypass - adverse effects (45) 45
cells, cultured (45) 45
drug therapy (45) 45
kinases (45) 45
peptides (45) 45
proline - analogs & derivatives (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1266) 1266
Japanese (15) 15
Russian (5) 5
French (3) 3
German (3) 3
Czech (1) 1
Italian (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
GENETIC-VARIATION | IL28B | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1195 - 1206
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1207 - 1217
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2012, Volume 35, Issue 6, pp. 647 - 662
Journal Article
Hepatology, ISSN 0270-9139, 03/2013, Volume 57, Issue 3, pp. 974 - 984
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 14, pp. 1292 - 1303
Journal Article